Device and method of creating aerosolized mist of respiratory drug
Patent 5934272 Issued on August 10, 1999. Estimated Expiration Date: October 27, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
128/200.22, Gas flow induced by expansion chamber device (e.g., piston/cylinder ram, squeeze bulb, etc.)128/200.14, LIQUID MEDICAMENT ATOMIZER OR SPRAYER128/204.23Means for sensing condition of user's body
Devices, packaging and methodology for efficiently and repeatably creating aerosolized bursts of a formulation of respiratory drug are disclosed. Devices are hand-held, self-contained units which are automatically actuated at the same release point in a patient's inspiratory flow cycle. The release point is automatically determined either mechanically or, more preferably calculated by a microprocessor which receives data from a sensor making it possible to determine inspiratory flow rate and inspiratory volume. The device is loaded with a cassette comprised of an outer housing which holds a package of individual collapsible containers of formulation which comprises a respiratory drug useful in topically treating lung tissue. Actuation of the device forces respiratory drug through a porous membrane of the container which membrane has pores having a diameter in the range of about 0.25 to 6.0 microns. The porous membrane is positioned in alignment with a surface of a channel through which a patient inhales air. The flow profile of air moving through the channel is such that the flow at the surface of the channel is less than the flow rate at the center of the channel. The membrane is designed so that it protrudes outward at all times or is made flexible so that when respiratory drug formulation is forced against and through the membrane the flexible membrane protrudes outward beyond the flow boundary layer of the channel into faster moving air. Because the membrane protrudes into the faster moving air of the channel the particles of aerosol formed are less likely to collide allowing for the formation of a burst of fine aerosol mist with uniform particle size.
Colthorpe, P. et al., "The pharmacokinetics of Pulmonary-Delivered Insulin:A comparison of intratracheal and aerosol administration to the rabbit", 1992, Pharmaceutical Research, 9:764-768
Daman, H.R., "Pulmonary function testing:Use of the peak expiratory flow rate in an out-patient or office setting", 1984, Journal of Asthma, 21:331-337
Evans, R. et al., "National trends in the morbidity and mortality of asthma in the US", 1987, Chest, 91(Supp.):65S-74S
Gourlay, G.K. et al., "Fetanyl blood concentration-analgesic response relationship in the treatment of postoperative pain", 1988, Anesth. Analg. 67:329-337
Jackson, R. et al., "International trends in asthma mortality: 1970 to 1985", 1988, Chest, 94:914-919
Jaffe, A.B. et al., Rats self-administer sufentanil in aerosol form
Janson-Bjerklie, S. et al., "Effect of peak flow information on patterns of self-care in adult asthma", 1988, Heart & Lung, 17:543-549
Kohler, D., "Aerosols for Systemic Treatment", 1990, Lung, Suppl.:677-684
Lauber, B.L. et al., "Deposition, Clearance, and Effects in the Lung", Journal of Aerosol Medicine, 4:286
Lehmann, K.A. et al., "Transdermal fentanyl for the treatment of pain after major urological operations", 1991, Eur. J. Clin. Pharmacol. 41:17-21
Malo, J. et al., Four-times-a-day dosing frequency is better than a twice-a-day regimen in subjects requiring a high-dose inhaled steroid, budesonide, to control moderate to severe asthma, 1989, Am. Rev. Respir. Dis. 140:624-628
Miller, R., "Anaesthesia", (2nd Edition), 1986, Churchill Livingstone, 1:762
Moses, A.C. et al., Insulin administered intranasally as an insulin-bile salt aerosol-Effectiveness and Reproducibility in Normal and Diabetic Subjects, 1983, Diabetes, 32:1040-1047
Newman, S.P. et al., "Deposition of pressurized aerosols in the human respiratory tract", 1981, Thorax, 36:52-55
Newman, S.P. et al., "How should a pressurized ଲ-adrenergic bronchodilator be inhaled?", 1981, Eur. J. Respir. Dis. 62:3-21
Newman, S.P. et al., "Deposition of pressurized suspension aerosols inhaled through extension devices", 1981, Am. Rev. Respir. Dis. 124:317-320
Newman, S.P., "Deposition and Effects of Inhalation Aerosols", 1983, (2 ed.), Churchill Livingstone
Nieminen, M.M., "Aerosol deposition in automatic dosimeter nebulization", 1987, Eur. J. Respir. Dis. 71:145-152
Nowak, R. et al., Comparison of peak expiratory flow and FEV1 admission criteria for acute bronchial asthma, 1982, Annals of Emergency Medicine, 11:64-69
Rapp, R.P. et al., Patient-controlled analgesia:A review of effectiveness of therapy and an evaluation of currently available devices, 1989, DICP, The Annals of Pharmacotherapy 23:899-904
Rosenberg, M., "Patient-controlled analgesia", 1992, J. Oral Maxillofac. Surg. 50:386-389
Rowbotham, D.J. et al., "A disposable device for patient-controlled analgesia with fentanyl", 1989, Anaesthesia, 44:922-924
Ryder, E., "The history of patient-controlled analgesia", 1991, Journal of Intravenous Nursing 14:372-381
Salzman, R.,"Intranasal aerosolized insulin mixed-meal studies and long-term use in type 1 diabetes", 1985, New England Journal of Medicine, 213:1078-1084
Sears et al., "Increasing asthma mortality--fact or artifact?", 1988, Journal of Allergy and Clinical Immunology, 82:957-960
October 27, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
